Pediatric Nephrology

, Volume 25, Issue 5, pp 919–925 | Cite as

Risk factors in community-acquired urinary tract infections caused by ESBL-producing bacteria in children

  • Rezan Topaloglu
  • Ilkay Er
  • Bahar Guciz Dogan
  • Yelda Bilginer
  • Fatih Ozaltin
  • Nesrin Besbas
  • Seza Ozen
  • Aysin Bakkaloglu
  • Deniz Gur
Original Article


In this study, risk factors were investigated in children with community-acquired urinary tract infections (UTI) caused by extended-spectrum beta-lactamases (ESBL)-producing E. coli or Klebsiella spp. One hundred and fifty-five patients were diagnosed with ESBL-positive UTI (case group) in the outpatient clinics of Hacettepe University Children’s Hospital between 1 January 2004 and 31 December 2006. A control group, 155 out of 4,105 children, was matched by age and sex among children with ESBL-negative UTI. A total of 310 patients’ files were evaluated retrospectively. As regards the symptoms of UTI, no statistical differences were seen between the two groups. Although the most frequently isolated microorganism was E. coli in both groups, Klebsiella spp. was found to be more frequent in those diagnosed with ESBL(+) UTI (p < 0.001). Having an underlying disease and hospitalization, infections, and use of antibiotics within the last 3 months were found to be potential risk factors (p < 0.001). With conditional logistic regression analysis, having an underlying disease and hospitalization within the last 3 months were identified as independent risk factors for ESBL(+) UTI. In conclusion, the recognition of risk factors for UTI, caused by ESBL(+) bacteria in children, may aid in the identification of high-risk cases and may enable proper management of these patients.


Extended-spectrum beta-lactamases (ESBL)-producing bacteria Urinary tract infection Community-acquired infection Risk factors Children 


  1. 1.
    Bradford PA (2001) Extended-spectrum ß-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14:933–951CrossRefPubMedGoogle Scholar
  2. 2.
    Livermore DM (2003) Bacterial resistance origins, epidemiology and impact. Clin Infect Dis 36 [Suppl 1]:S11–S23CrossRefPubMedGoogle Scholar
  3. 3.
    Philippon A, Arlet G, Lagrange PH (1994) Origin and impact of plasmid mediated extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 13 [Suppl 1]:17–29CrossRefGoogle Scholar
  4. 4.
    Pitout DD, Laupland KB (2008) Extended-spectrum ß-lactamase producing Enterobacteriaceae: an emerging public health concern. Lancet 8:159–166CrossRefGoogle Scholar
  5. 5.
    Gür D, Pitt TL, Hall LMC, Akalın HE, Livermore DM (1992) Diversity of klebsiellae with extended-spectrum beta-lactamases at a Turkish University Hospital. J Hosp Infect 22:163–166CrossRefPubMedGoogle Scholar
  6. 6.
    Meyer KS, Urban C, Eagan JA, Berger BJ (1993) Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 119:353–358PubMedGoogle Scholar
  7. 7.
    Naumovski L, Quinn JP, Miyashiro D, Bush PK, Singer SB, Graves D, Palzkill T, Arvin AM (1992) Outbreak of ceftazidime resistance due to a novel extended-spectrum ß-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 36:1991–1996PubMedGoogle Scholar
  8. 8.
    Schiappa DA, Hayden MK, Matushek MG, Hashemi F, Sulvian J, Smith KY, Miyashiro D, Quinn JP, Weinstein RA, Trenholme GM (1996) Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 174:529–536PubMedGoogle Scholar
  9. 9.
    Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, Bonomo RA, Rice LB, McCormack JG, Yu VL (2001) Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum ß-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 39:2206–2212CrossRefPubMedGoogle Scholar
  10. 10.
    Paterson DL, Ko WC, Gottberg AV, Mohapatra S, Casellas JM, Goossens H, Mülazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL (2004) Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum ß-lactamases. Clin Infect Dis 39:31–37CrossRefPubMedGoogle Scholar
  11. 11.
    Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, Kim JH, Kim EC (2002) Bloodstream infections by extended-spectrum ß-lactamase producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 46:1481–1491CrossRefPubMedGoogle Scholar
  12. 12.
    Zaoutis TE, Goyal MG, Chu JH, Coffin SE, Bell LM, Nachamkin I, McGowan KL, Bilker WB, Lautenbach E (2009) Risk factors and outcomes of bloodstream infection caused by extended-spectrum ß-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics 115:942–949CrossRefGoogle Scholar
  13. 13.
    Hibberd PL, Jacoby GA (1994) Multiple drug resistant Klebsiella pneumoniae (MDRKP) strains: predictors of acquisition and mortality [abstract no C46]. In: Program and abstracts of the 34th Interscience Conference Antimicrobial Agents and Chemotherapy (Orlando, FL). American Society for Microbiology, Washington, DC, p 87Google Scholar
  14. 14.
    Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, Raz R (2004) Risk factors for the development of extended-spectrum ß-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 23:163–167CrossRefPubMedGoogle Scholar
  15. 15.
    Calbo E, Romani V, Xercavins M, Gomez L, Vidal CG, Quintana S, Vila J, Garau J (2006) Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum ß-lactamases. J Antimicrob Chemother 57:780–783CrossRefPubMedGoogle Scholar
  16. 16.
    Kuo KC, Shen YH, Hwang KP (2007) Clinical implications and risk factors of extended-spectrum beta-lactamase producing Klebsiella pneumoniae infection in children: a case-control retrospective study in a medical center in southern Taiwan. J Microbiol Immunol Infect 40:248–254PubMedGoogle Scholar
  17. 17.
    Polhamus B, Dalenius K, Thompson D, Scanlon K, Borland E, Smith B, Grummer-Strawn L (2004) Pediatric Nutrition Surveillance 2002 Report, Atlanta, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention
  18. 18.
    Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. CLSI document. M100-S17 [ISBN 1-56238-625-5]. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA, 2007Google Scholar
  19. 19.
    Kleinbaum DG (1994) Logistic regression. In: Analysis of matched data using logistic regression. A self-learning text. Springer, New York Berlin Heidelberg, pp 227–249Google Scholar
  20. 20.
    Pitout JDD, Nordmann P, Laupland KB, Poirel L (2005) Emergence of Enterobacteriaceae producing extended-spectrum ß-lactamases (ESBLs) in the community. J Antimicrob Agents 56:52–59CrossRefGoogle Scholar
  21. 21.
    Ena J, Arjona F, Martinez-Peinado C, Lopez-Perezagua M, Amador C (2006) Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase producing Escherichia coli. Urology 68:1169–1174CrossRefPubMedGoogle Scholar
  22. 22.
    Coque TM, Baquero F, Canton R (2008) Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Eurosurveillance 13:1–11Google Scholar
  23. 23.
    Du B, Long Y, Liu H, Chen D, Liu D, Xu Y, Xie X (2002) Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae blood stream infection: risk factors and clinical outcome. Intensive Care Med 28:1718–1723CrossRefPubMedGoogle Scholar
  24. 24.
    Colodner R (2005) Extended-spectrum beta-lactamases: a challenge for clinical microbiologists and infection control specialists. Am J Infect Control 33:104–107CrossRefPubMedGoogle Scholar
  25. 25.
    Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D (2004) Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum ß-lactamases in UK. J Antimicrob Chemother 54:735–743CrossRefPubMedGoogle Scholar
  26. 26.
    Yuksel S, Ozturk B, Kavaz A, Ozcakar B, Acar B, Guriz H, Aysev D, Ekim M, Yalcinkaya F (2006) Antibiotic resistance of urinary tract pathogens and evaluation of empirical treatment in Turkish children with urinary tract infections. Int J Antimicrob Agents 28:413–416CrossRefPubMedGoogle Scholar
  27. 27.
    Akram M, Shahid M, Khan AU (2007) Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. Ann Clin Microb 6:4–7CrossRefGoogle Scholar
  28. 28.
    Gupta V, Yadav A, Joshi RM (2002) Antibiotic resistance pattern in uropathogens. Indian J Med Microbiol 20:96–98PubMedGoogle Scholar
  29. 29.
    Akata F, Tatman-Otkun M, Özkan E, Tansel O, Otkun M, Tugrul M (2003) Prevalence of extended spectrum beta lactamases produced by nosocomial isolates of enterobacteriacae in Trakya University Hospital, Turkey. New Microbiol 26:257–262PubMedGoogle Scholar
  30. 30.
    Yılmaz E, Akalın H, Özbey S, Kordan Y, Sınırtaş M, Gürcüoğlu E, Özakın C, Heper Y, Mıstık R, Helvacı S (2008) Risk factors in community-acquired/onset urinary tract infections due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. J Chemother 20:581–585PubMedGoogle Scholar
  31. 31.
    Rodriguez-Bano JR, Navarro MD, Romero L, Martinez-Martinez L, Muniain MA, Perea EJ, Perez-Cano R, Pascual A (2004) Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 42:1089–1094CrossRefPubMedGoogle Scholar

Copyright information

© IPNA 2010

Authors and Affiliations

  • Rezan Topaloglu
    • 1
  • Ilkay Er
    • 2
  • Bahar Guciz Dogan
    • 3
  • Yelda Bilginer
    • 1
  • Fatih Ozaltin
    • 1
  • Nesrin Besbas
    • 1
  • Seza Ozen
    • 1
  • Aysin Bakkaloglu
    • 1
  • Deniz Gur
    • 4
  1. 1.Department of Pediatric NephrologyHacettepe University Faculty of MedicineAnkaraTurkey
  2. 2.Department of PediatricsHacettepe University Faculty of MedicineAnkaraTurkey
  3. 3.Public MedicineHacettepe University Faculty of MedicineAnkaraTurkey
  4. 4.Microbiology LaboratoryHacettepe University Children’s HospitalAnkaraTurkey

Personalised recommendations